All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Catch up with our live Twitter coverage from the 49th Annual Meeting of the EBMT.
CARTITUDE-2 Cohort C: Efficacy and safety of cilta-cel in patients with relapsed/refractory MM
We summarize the latest efficacy and safety findings of cilta-cel in patients with progressive MM after non-cellular anti-BCMA immunotherapy from Cohort C...
Subscribe to get the best content related to multiple myeloma delivered to your inbox